Cart
sales@molnova.com
JMS-17-2
CAS No. 1380392-05-1
JMS-17-2( JMS-17-2 | JMS172 | JMS 17 2 | JMS17-2 | JMS-172 )
Catalog No. M11574 CAS No. 1380392-05-1
JMS-17-2 is a potent and selective antagonist of CX3CR1 with IC50 of 0.32 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 43 | In Stock |
|
| 5MG | 71 | In Stock |
|
| 10MG | 120 | In Stock |
|
| 25MG | 210 | In Stock |
|
| 50MG | 327 | In Stock |
|
| 100MG | 484 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameJMS-17-2
-
NoteResearch use only, not for human use.
-
Brief DescriptionJMS-17-2 is a potent and selective antagonist of CX3CR1 with IC50 of 0.32 nM.
-
DescriptionJMS-17-2 is a potent and selective antagonist of CX3CR1 with IC50 of 0.32 nM, displays significant selectivity for CX3CR1 over other chemokine receptors such CXCR2, CXCR1, and CXCR4 (IC50>1 uM); effectively blocks FKN-induced ERK phosphorylation, also significantly reduces the migration of breast cancer cells in vitro; impairs metastatic seeding and colonization of breast cancer cells, shows long-term anti-tumor effects in vivo.
-
In Vitro——
-
In VivoAnimal Model:SCID mice (~25g) with MDA-231 xenograftDosage:10 mg/kg Administration:Aministered i.p.; twice a day for three weeks Result:Caused a dramatic reduction of tumors in both skeleton and visceral organs.
-
SynonymsJMS-17-2 | JMS172 | JMS 17 2 | JMS17-2 | JMS-172
-
PathwayGPCR/G Protein
-
TargetChemokine Receptor
-
RecptorChemokine Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1380392-05-1
-
Formula Weight419.953
-
Molecular FormulaC25H26ClN3O
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 25 mg/mL (59.53 mM)
-
SMILESO=C1C2=CC=CN2C3=C(C=CC=C3)N1CCCN4CCC(C5=CC=C(Cl)C=C5)CC4
-
Chemical Name5-[3-[4-(4-Chlorophenyl)-1-piperidinyl]propyl]pyrrolo[1,2-a]quinoxalin-4(5H)-one
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Shen F, et al. Mol Cancer Res. 2016 Jun;14(6):518-27.
2. Stout MC, et al. Biochem Biophys Res Commun. 2018 Jan 15;495(3):2264-2269.
3. Naya A, et al. J Med Chem. 2001 Apr 26;44(9):1429-35.
molnova catalog
related products
